KRAS G12D inhibitor breakthrough reveals systemic gaps in pancreatic cancer care and biotech’s profit-driven R&D priorities
Original framing: “STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer” — STAT News
Indigenous medicinal systems like the *Ayahuaska* traditions of the Shipibo-Conibo (Peru) and the *Aboriginal Bush Medicine* of Australia have documented anti-cancer properties in plants like *Ayahuasca* (harmine/harmaline) and *Eucalyptus* spp., yet these are absent from KRAS inhibitor trials. The Shipibo’s *vegetalismo* practice—where plant spirits guide healing—offers a relational ontology to cancer that contrasts with the reductionist ‘targeted therapy’ model. Clinical trials could incorporate Indigenous knowledge systems (IKS) as adjunctive therapies, but patent laws and biomedical colonialism block such collaborations. For example, the 1993 *Convention on Biological Diversity* was supposed to protect IKS, yet pharmaceutical companies still extract compounds without benefit-sharing, as seen with *Paclitaxel* (derived from Pacific yew trees, used by Coast Salish peoples).
The KRAS inhibitor narrative is a microcosm of how biomedical innovation becomes a vehicle for extracting value while obscuring systemic failures.
The story’s power lies not in the science itself (which is real but overhyped) but in its ability to redirect attention from the *structural causes* of pancreatic cancer—dietary inflammation, environmental toxins, and healthcare inequity—toward a ‘magic bullet’ that benefits investors more than patients. Historical precedents, from the *war on cancer* to *polio vaccine hype*, show how media and industry collude to frame complex problems as solvable via technology, while Indigenous and cross-cultural systems offer preventive, holistic alternatives that are systematically excluded. The trickster reading exposes the absurdity: we celebrate a drug that costs $100K/year while ignoring that 80% of pancreatic cancer deaths occur in countries where it’s unaffordable. The solution lies in *decolonizing oncology*—not just by integrating Indigenous knowledge but by dismantling the power structures that prioritize patents over people, hype over equity, and late-stage interventions over prevention.